Roth Capital Resumes Cempra, Inc. (CEMP) at Buy

Roth Capital resumes coverage on Cempra, Inc. (NASDAQ: CEMP) with a Buy rating and a price target of $42.00.

Analyst Debjit Chattopadhyay commented, "Cempra is a de-risked, anti-infective, pure-play, in our view. With Solitaire-Oral phase-3 in the bag we have high expectations on a positive outcome from Solitaire-IV, during YE15, expect NDA by mid-16, and launch during 2Q17. Additionally, the expanded the clinical profile of solithromycin along with its second phase 3-ready asset should generate consistent news flow over the next 12 to 18 months."

For an analyst ratings summary and ratings history on Cempra, Inc. click here. For more ratings news on Cempra, Inc. click here.

Shares of Cempra, Inc. closed at $36.16 yesterday.

You May Also Be Interested In

• UBS Downgrades DiaSorin SpA (DIA:IM) (DSRLF) to Sell
• SharkNinja (SN) PT Raised to $219.10 at UBS
• Compass Point Reiterates Buy Rating on CoreWeave (CRWV)